NDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPCON-A is a fixed-dose combination ophthalmic solution containing pheniramine maleate (antihistamine) and naphazoline hydrochloride (decongestant) for topical eye use. It is indicated for temporary relief of ocular itching and redness due to allergies or minor irritation. The dual mechanism addresses both allergic inflammation and vascular congestion in the eye.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting defensive positioning and potential headcount reductions as market consolidation accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPCON-A offers exposure to mature product lifecycle management, competitive strategy in generics-dominated markets, and Bausch + Lomb's ophthalmology portfolio. Career growth is limited on this specific asset; roles focus on defending market share rather than expansion, making it a stable but non-growth opportunity.
Brand ManagerProduct Manager
Worked on OPCON-A at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.